With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.166330-10-5,(Oxybis(2,1-phenylene))bis(diphenylphosphine),as a common compound, the synthetic route is as follows.
The resulting precursor P – 3 (4.8 g, 10 mmol, 1.0 equivalent), silver oxide (1.2 g, 5 mmol, 50percent yield), solvent acetonitrile 50 ml are sequentially added into a 100 ml flask, 50 ¡ãC light reaction 12 hours; filter, collecting the filtrate, dryness, a colorless solid. The solid with thecopperpowder (0.64 g, 10 mmol, 1.0 equivalent) as for 100 ml flask, add anhydrous non-oxygen second grade nitrile 50 ml, stirring at the room temperature reaction 5 hours; add ligand POP (4.3 g, 8 mmol, 80percent yield), stirring at the room temperature reaction 3 hours; filter, to remove the insoluble solid, collecting the filtrate, reduced pressure drying, be light green solid, that is the crude product. The crude product is dissolved inmethylenechloridesolvent, slow volatilization of the solvent, a large number of light yellow crystalline precipitation, filtration to obtain pure complex [(NHC – 3) Cu (POP)]+PF6-(8.1 G, 7.5 mmol), yield is 75percent., 166330-10-5
The synthetic route of 166330-10-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Luoyang Normal College; Wang Zhiqiang; Zhang Zhiqiang; Xu Liancai; Sun Xiaojuan; Xu Chen; Li Hongmei; (21 pag.)CN104610285; (2017); B;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate